Novel Cationic Lipids for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as RNA, face challenges including instability in plasma due to nuclease digestion and limited ability to enter intracellular compartments for effective translation.
Innovation Solution
The development of novel cationic lipids that form mRNA lipid nanoparticle compositions, which include cationic and/or ionizable amino lipids, neutral lipids, polymer conjugated lipids, and steroids, to enhance stability and cellular uptake of nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If free RNA is used for delivery, then simplicity is maintained, but it is readily digested by nuclease in the plasma
Solution Approach 1:
The patent introduces lipid nanoparticles as an intermediary carrier system that protects RNA from nuclease degradation in plasma. The lipid nanoparticle formulation acts as a mediator between the RNA and the cellular target, preventing enzymatic breakdown while maintaining delivery functionality.
Solution Approach 2:
The patent employs composite lipid nanoparticle structures combining cationic lipids, neutral lipids, cholesterol, and PEGylated lipids. This composite material approach provides both protective properties against degradation and functional properties for cellular uptake, resolving the contradiction between simplicity and stability.
2Ease of manufacture
If free RNA is used for delivery, then simplicity is maintained, but its ability to enter intracellular compartments is limited
Solution Approach 1:
The lipid nanoparticle serves as an intermediary that facilitates RNA entry into intracellular compartments. The cationic lipids in the nanoparticle interact with cell membranes and endocytic pathways, enabling efficient delivery of RNA to intracellular targets while maintaining formulation simplicity.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the delivery system by forming lipid nanoparticles with specific size, charge, and composition characteristics. These parameter changes enhance cellular uptake efficiency while keeping the overall delivery approach relatively simple.
3Productivity
If conventional cationic lipids are used, then cellular uptake is achieved, but toxicity and risk to the patient increase
Solution Approach 1:
The patent applies local quality modification by using PEGylated lipids that provide steric hindrance and reduced non-specific interactions at the lipid-water interface. This localized modification at the nanoparticle surface reduces toxicity while preserving cellular uptake functionality.
Solution Approach 2:
The patent changes key parameters of the cationic lipids including PEGylation, chain length, and head group modifications to optimize the balance between cellular uptake efficiency and toxicity. These parameter adjustments create a therapeutic window that minimizes harmful effects.
4Reliability
If lipid nanoparticles are formulated with multiple lipid components, then protection from degradation and cellular uptake are improved, but formulation complexity increases
Solution Approach 1:
The patent designs a multi-component lipid nanoparticle system where each component serves multiple functions: cationic lipids provide cellular uptake and RNA binding, neutral lipids provide structural stability, cholesterol modulates membrane properties, and PEGylated lipids provide stealth properties. This multi-functionality justifies the increased formulation complexity.
Solution Approach 2:
The patent employs a composite lipid formulation where synergistic interactions between different lipid components achieve enhanced protective and delivery properties that single components cannot provide alone, making the increased complexity necessary for optimal performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These lipid nanoparticle compositions effectively protect nucleic acids from degradation, facilitate their intracellular delivery, and provide optimized drug delivery, ensuring therapeutic efficacy with reduced toxicity.
Implementation Method 1
These compositions generally comprise one or more 'cationic' lipids, including neutral lipids which contain polyunsaturated lipids (e.g. phospholipids)... Cationic lipids include amine-containing lipids, are easily protonated.
Data Source
AI summary
The present invention relates to lipid compounds that can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and/or analogues thereof, and/or polymer conjugated lipids to form lipid nanoparticles for delivery of therapeutic and/or prophylactic agents. In some examples, lipid nanoparticles are used to deliver nucleic acids, such as messenger RNA and/or antisense RNA. Methods of using these lipid nanoparticles to treat and/or prevent various diseases are also provided.In one embodiment, a compound having the structure of formula (I) below is provided:or a salt or isomer thereof or an N-oxide thereof, wherein RI is as defined herein.Pharmaceutical compositions comprising one or more compounds of the aforementioned structural formula (I) and therapeutic and/or prophylactic agents are also provided. In some embodiments, the pharmaceutical composition further comprises one or more components selected from neutral lipids, charged lipids, steroids, and polymer conjugated lipids. These compositions are useful for forming lipid nanoparticles to deliver therapeutic and/or prophylactic agents.In other embodiments, the invention provides a method of administering a therapeutic agent and/or prophylactic agent to a subject in need thereof, the method is that pharmaceutical composition comprising lipid nanoparticles and a therapeutic agent and/or prophylactic agent with a compound of formula (I) was prepared, and delivering the composition to the subject.